文献速递胸部儿科影像MR

PREFUL MRI监测囊性纤维化患者接受elexacaftor-tezacaftor-ivacaftor治疗后的灌注与通气变化:可行性研究

PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
PubMed 文献 · Radiol Cardiothorac Imaging · 2024-01-01

本研究为多中心前瞻性研究的二次分析,纳入23例12岁及以上囊性纤维化患者,在ETI治疗前及治疗后8-16周行PREFUL MRI、肺量计、汗液氯离子检测及肺清除指数评估。结果显示区域通气缺陷百分比从18%降至9%(P=.003),灌注缺陷百分比从26%降至19%(P=.002),通气血流匹配正常区域从52%增至73%,表明PREFUL MRI用于半自动定量评估ETI治疗后的灌注和通气变化具有可行性。

要点

  • PREFUL MRI可半自动定量评估囊性纤维化患者ETI治疗前后的区域通气和灌注变化。
  • ETI治疗后区域通气缺陷百分比从18%降至9%(P=.003),灌注缺陷百分比从26%降至19%(P=.002)。
  • 目视评估的灌注评分与PREFUL灌注(P=.11)及通气血流匹配值(P=.38)均无相关性。

核心结论

  • 本研究证明PREFUL MRI可用于半自动定量评估囊性纤维化患者接受ETI治疗后灌注和通气变化的可行性。

研究设计与样本

  • 多中心前瞻性研究的二次分析,纳入23例12岁及以上囊性纤维化患者,在ETI治疗前及治疗后8-16周行PREFUL MRI、肺量计、汗液氯离子检测和肺清除指数评估;采用二维冠状面动态梯度回波MR图像通过自动化定量流程提取PREFUL通气和灌注参数。

关键影像表现/征象

  • ETI治疗后区域通气缺陷百分比从18%(IQR:14%-25%)降至9%(IQR:6%-17%)(P=.003)。
  • ETI治疗后灌注缺陷百分比从26%(IQR:18%-36%)降至19%(IQR:13%-24%)(P=.002)。
  • 通气和灌注匹配正常(健康)区域从52%(IQR:47%-68%)增至73%(IQR:61%-83%)。
  • 目视评估的灌注评分与PREFUL灌注无相关性(P=.11),与通气血流匹配值亦无相关性(P=.38)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To assess the feasibility of monitoring the effects of elexacaftor-tezacaftor-ivacaftor (ETI) therapy on lung ventilation and perfusion in people with cystic fibrosis (CF), using phase-resolved functional lung (PREFUL) MRI. Materials and Methods This secondary analysis of a multicenter prospective study was carried out between August 2020 and March 2021 and included participants 12 years or older with CF who underwent PREFUL MRI, spirometry, sweat chloride test, and lung clearance index assessment before and 8-16 weeks after ETI therapy. For PREFUL-derived ventilation and perfusion parameter extraction, two-dimensional coronal dynamic gradient-echo MR images were evaluated with an automated quantitative pipeline. T1- and T2-weighted MR images and PREFUL perfusion maps were visually assessed for semiquantitative Eichinger scores. Wilcoxon signed rank test compared clinical parameters and PREFUL values before and after ETI therapy. Correlation of parameters was calculated as Spearman ρ correlation coefficient. Results Twenty-three participants (median age, 18 years [IQR: 14-24.5 years]; 13 female) were included. Quantitative PREFUL parameters, Eichinger score, and clinical parameters (lung clearance index = 21) showed significant improvement after ETI therapy. Ventilation defect percentage of regional ventilation decreased from 18% (IQR: 14%-25%) to 9% (IQR: 6%-17%) (P = .003) and perfusion defect percentage from 26% (IQR: 18%-36%) to 19% (IQR: 13%-24%) (P = .002). Areas of matching normal (healthy) ventilation and perfusion increased from 52% (IQR: 47%-68%) to 73% (IQR: 61%-83%). Visually assessed perfusion scores did not correlate with PREFUL perfusion (P = .11) nor with ventilation-perfusion match values (P = .38). Conclusion The study demonstrates the feasibility of PREFUL MRI for semiautomated quantitative assessment of perfusion and ventilation changes in response to ETI therapy in people with CF. Keywords: Pediatrics, MR-Functional Imaging, Pulmonary, Lung, Comparative Studies, Cystic Fibrosis, Elexacaftor-Tezacaftor-Ivacaftor Therapy, Fourier Decomposition, PREFUL, Free-Breathing Proton MRI, Pulmonary MRI, Perfusion, Functional MRI, CFTR, Modulator Therapy, Kaftrio Clinical trial registration no. NCT04732910 Supplemental material is available for this article. © RSNA, 2024.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. Dohna M, Voskrebenzev A, Klimeš F, et al. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study. Radiol Cardiothorac Imaging. 2024. PMID: 38573129. doi:10.1148/ryct.230104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。